Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Pharmacogenomics Journal

Volumn 12, Issue 6, 2012, Pages 468-475

  Koutras, A K ^a   Antonacopoulou, A G ^a   Eleftheraki, A G ^b   Dimitrakopoulos, F I ^a   Koumarianou, A ^c   Varthalitis, I ^d   Fostira, F ^e   Sgouros, J ^f   Briasoulis, E ^g   Bournakis, E ^h   Bafaloukos, D ⁱ   Bompolaki, I ^d   Galani, E ⁱ   Kalogeras, K T ^b,j   Pectasides, D ^c   Fountzilas, G ^j   Kalofonos, H P ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d Chania General Hospital St George   (Greece)

^e INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

more..

Author keywords

bevacizumab; chemotherapy; clinical outcome; colorectal cancer; polymorphisms; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VEGF GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870054412     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.37     Document Type: Article

References (31)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1996; 1: 27-31.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
4. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-560.
5. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
7. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
8. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
9. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26: 4899-4905.
10. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J ClinOncol 2008; 26: 4672-4678.
11. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20: 227-230.
12. Pectasides DG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papaxoinis G et al. Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). J Clin Oncol 2010; 28: 15s (suppl; abstr 3541).
13. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008; 111: 157-163.
14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
15. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229-235.
17. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8: 2496-2508.
18. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297-5302.
19. Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C4T) gene and colon cancer in Korea. Anticancer Res 2008; 28: 1271-1276.
20. Park HM, Hong SH, Kim JW, Oh D, Hwang SG, An HJ et al. Genderspecific association of the VEGF-2578C 4 A polymorphism in Korean patients with colon cancer. Anticancer Res 2007; 27: 2535-2539.
21. Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A et al. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci 2008; 5: 80-86.
22. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008; 14: 62-66.
23. Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H et al. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol 2008; 134: 591-595.
24. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J 2011; 11: 53-60, (e-pub ahead of print, 2 February 2010).
25. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008; 14: 7554-7563.
26. Mohammadi M, Ollier W, Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol 2003; 64: S125.
27. Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M et al. Dosefinding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer 2010; 103: 1529-1535, (e-pub ahead of print, 12 October 2010).
28. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871-7877.
29. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011; 26: 143-151, (e-pub ahead of print, 29 December 2010).
30. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 2006; 96: 209-215.
31. Coltelli L, Allegrini G, Orlandi P, Giuntini N, Al?́ G, Fioravanti A et al. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics 2009; 10: 1225-1229.